| Literature DB >> 36013067 |
Mariela Corrales1,2, Alba Sierra1,2, Olivier Traxer1,2.
Abstract
Moses technology was born with the aim of controlling the Moses effect present in every single Ho:YAG laser lithotripsy. The capacity to divide the energy pulse into two sub-pulses gained popularity due to the fact that most of the energy would be delivered in the second pulse. However, is this pulse modulation technique really better for endocorporeal laser lithoripsy? A review of the literature was performed and all relevant clinical trials of Moses 1.0 and 2.0, as well as the lab studies of Moses 2.0 carried out up to June 2022 were selected. The search came back with 11 clinical experiences (10 full-text clinical trials and one peer-reviewed abstract) with Moses 1.0 and Moses 2.0, and three laboratory studies (peer-reviewed abstracts) with Moses 2.0 only. The clinical experiences confirmed that the MT (1.0) has a shorter lasing time but lower laser efficacy, because it consumes more J/mm3 when compared with the LP Ho:YAG laser (35 W). This gain in lasing time did not provide enough savings for the medical center. Additionally, in most comparative studies of MT (1.0) vs. the regular mode of the HP Ho:YAG laser, the MT did not have a significant different lasing time, operative time or stone-free rate. Clinical trials with Moses 2.0 are lacking. From what has been published until now, the use of higher frequencies (up to 120 Hz) consumes more total energy and J/mm3 than Moses 1.0 for similar stone-free rates. Given the current evidence that we have, there are no high-quality studies that support the use of HP Ho:YAG lasers with MT over other lasers, such as LP Ho:YAG lasers or TFL lasers.Entities:
Keywords: Lumenis; Moses; endourology; holmium; kidney; laser; lithiasis; lithotripsy; stones; ureter
Year: 2022 PMID: 36013067 PMCID: PMC9409732 DOI: 10.3390/jcm11164828
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Flow chart of the literature review.
Clinical experience with Moses 1.0. I: Intervention, n: sample size, SD: Standard deviation, RCT: Randomized control trial, P: Prospective, R: Retrospective, RC: Retrospective comparative, PC: Prospective comparative, RM: Regular mode, MC: Moses contact, MD: Moses distance, D: Dusting, F: Fragmentation, SFR: stone-free rate, N.A: Not available, *: statistically significant difference (p < 0.05), **: mostly fragmented ureteral stones.
| Author, Year, Type of Study | I |
| Type of Laser | Pulse Modulation Setting: | Fiber Size (μ) | Laser Settings | Stone Size Mean ± SD | Stone Volume | Stone Density | Stone Location | Lasing Time | Operative Time | Energy | Ablation Speed (mm3/s) | J/mm3 | SFR (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leotsakos et al., 2020, R [ | Ultra-mini PCNL | 12 | Lumenis Moses PulseTM 120 H | MC | 550 | 0.6–0.8 J/80 Hz | 3.15 | 7810.6 | 1252 | Kidney | 13 ± 16 | 86.4 ± 36.8 | 39.7 ± 52 | N.A | N.A | 91.7 |
| Reddy et al., 2021, P [ | Ultra-mini PCNL | 110 | Lumenis Moses PulseTM 120 H | MC and MD | 365 | 0.4–0.6 J/40–60 Hz | 1.75 | N.A | 1140 | Kidney | 7.9 | 38.6 | N.A | N.A | N.A | 100 |
|
| ||||||||||||||||
| Mullerad et al., 2017, P [ | URS | 34 | Lumenis Moses PulseTM 120 H | Moses: 23 | 200, 365, 550 | N.A | N.A | 781.9 median | 901.5 | Kidney or ureter | 6 (median) | N.A | 4.5 (median) | N.A | N.A | N.A |
| RM: 11 | 200, 365 | 422.5 median | 867 | 10 (median) | 6.4 (median) | |||||||||||
| Ibrahim et al., 2020, RCT [ | URS | 72 | Lumenis Moses PulseTM 120 H | Moses: 36 | 200 | D: 0.4 J/80 Hz | 1.7 ± 1.5 | N.A | 991 ± 213 | Kidney or ureter ** | 6.1 ± 9.8 | 41.1 ± 21.1 * | 10.8 ± 14.1 | N.A | N.A | 88.4 |
| RM: 36 | F: 1 J/10 Hz | 1.4 ± 0.97 | 841 ± 348 | 7.4 ± 5.7 | 50.9 ± 27.9 * | 11.1 ± 20.3 | 88.3 | |||||||||
| Wang et al., 2021, RC [ | URS | 216 | Lumenis Moses PulseTM 120 H | MC: 114 | 200 | 0.3 J/60 Hz | 1.2 | 674 ± 41 | 990 ± 150 | Kidney | 4.99 ± 1.06 * | 18.39 ± 5.13 * | N.A | N.A | N.A | 86.8 |
| RM: 102 | 1.2 | 683 ± 39 | 994 ± 150 | 5.94 ± 0.96 * | 21.17 ± 6.78 * | 85.3 | ||||||||||
| Knoedler et al., 2022, RC [ | URS | 176 | Lumenis Moses PulseTM 120 H | Moses: 110 | 200 | D: 0.3 J/80 Hz | 1.18 ± 0.79 | N.A | N.A | Kidney and/or ureter | 7.5 ± 11.1 | 43.5 ± 32.1 | 5.1 ± 6.7 | N.A | N.A | 52.3 |
| RM: 66 | F: 0.8 J/8 Hz | 1.16 ± 0.92 | 6.7 ± 7.9 | 39.8 ± 24.6 | 3.8 ± 4.8 | 65.3 | ||||||||||
|
| ||||||||||||||||
| Mekayten et al., 2019, RC [ | URS | 631 | Lumenis Moses PulseTM 120 H | Moses: 169 | 200, 365, 550 | 0.5 J/63 Hz * (mean) | N.A | 427 | 1085 * | Kidney or ureter | 3.3 * | 21.13 * | 4.7 ± 5 * | 0.8 * | 17.2 * | 84.5 |
| Ho:YAG | RM: 462 | 0.7 J/14 Hz * (mean) | 367 | 1022 * | 6.6 * | 31.84 * | 3.6 ± 4 * | 1.51 * | 13 * | 87.2 | ||||||
| Pietropaolo et al., 2021, RC [ | URS | 76 | Lumenis Moses | Moses: 38 | 200 | 0.4–0.8 J/20–25 Hz | 1.09 ± 0.4 | N.A | N.A | Kidney or ureter | N.A | 51.6 ± 17.1 * | N.A | N.A | N.A | 100 |
| Ho:YAG | RM: 38 | 0.4–0.8 J/12–18 Hz | 1.18 ± 0.4 | 82.1 ± 27.0 * | 97.3 | |||||||||||
Laboratory experience with Moses 2.0.
| MD Settings | SP Settings | Moses 2.0 (EFR) Settings | Results | |
|---|---|---|---|---|
| Whelan, P., et al., 2021, abstract [ | 0.3 J/80 Hz (24 W); | - | 0.2 J/120 Hz (24 W); | At comparable power settings, EFR had a superior stone ablation volume than MD at SD 0 mm. |
| 0.4 J/80 Hz (32 W) | 0.3 J/120 Hz (36 W) | |||
| Whelan, P., et al., 2021, abstract [ | 0.5 J/70 Hz (35 W) | 0.5 J/70 Hz (35 W) | 0.3 J/120 Hz (36 W) | Hard stones: |
| 0.6 J/80 Hz (48 W) | 0.6 J/80 Hz (48 W) | 0.4 J/100 Hz (40 W) | - EFR: Provides a more efficient popcorn lithotripsy. | |
| 1 J/20 Hz (20 W) | 1 J/20 Hz (20 W) | 0.5 J/100 Hz (50 W) | - EFR 0.5 J/90 Hz offers the greatest fragmentation among the other modes. | |
| 0.5 J/90 Hz (45 W) | Soft stones: EFR did not demonstrate benefits over the other modes, for a similar total power. | |||
| Whelan, P., et al., 2021, abstract [ | 0.3 J/80 Hz (24 W) | - | 0.2 J/120 Hz (24 W) | |
| 0.2 J/100 Hz (20 W) | 0.3 J is superior to 0.2 J at all frequencies | |||
| 0.2 J/80 Hz (16 W) | 0.3 J/120 Hz (36 W) | |||
| 0.3 J/100 Hz (30 W) |
Clinical experience with Moses technology. I: Intervention, n: sample size, SD: Standard deviation, SC: Single case report, P: Prospective, R: Retrospective, RC: Retrospective comparative, MD: Moses distance, SFR: stone-free rate.
| Author, Year, Type of Study | I |
| Type of Laser | Pulse Modulation Setting: | Fiber Size (μ) | Laser Settings | Stone Size Mean ± SD (cm) | Stone Volume | Stone Density | Stone Location | Lasing Time | Operative Time | Energy | Ablation Speed (mm3/s) | J/mm3 | SFR (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Khajeh et al., 2021, SCR [ | URS | 1 | Lumenis Moses PulseTM 120 H | Moses 2.0 | 230 | Debulk: | 1.7 | N.A | N.A | Kidney | 16 | 23 | 33.3 | N.A | N.A | N.A |
| 0.3 J/120 Hz | ||||||||||||||||
| Pop-dusting: | ||||||||||||||||
| 0.5 J/80 Hz | ||||||||||||||||
| Majdalany et al., 2021, RC [ | URS | 29 | Lumenis Moses PulseTM 120 H | Moses 1.0: 18 | 230 | 0.5 J/50–80 Hz | 0.94 | 242 | 784 | Kidney | 5.3 | 10.4 | 6.4 | 0.88 | 32.4 | 71 |
| Moses 2.0: 11 | 0.5 J/50–120 Hz | 368 | 865 | 7.0 | 14.3 | 12.4 | 0.97 | 47.8 | 90 | |||||||
| Rezakahn et al., 2021, P [ | URS | 12 | Lumenis Moses PulseTM 120 H | Moses 2.0 | 230 | Debulk: | 1.04 | N.A | 865 | Kidney | 6.9 | 15 | 12 | N.A | N.A | 82 |
| 0.2–0.3 J/100–120 Hz | ||||||||||||||||
| Pop-dusting: | ||||||||||||||||
| 0.5 J/80 Hz (MD) |